WO2002003989A3 - Use of substituted indole compounds for treating sphincter incontinence - Google Patents
Use of substituted indole compounds for treating sphincter incontinence Download PDFInfo
- Publication number
- WO2002003989A3 WO2002003989A3 PCT/US2001/021081 US0121081W WO0203989A3 WO 2002003989 A3 WO2002003989 A3 WO 2002003989A3 US 0121081 W US0121081 W US 0121081W WO 0203989 A3 WO0203989 A3 WO 0203989A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- formulae
- substituted indole
- indole compounds
- ethers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001271781A AU2001271781A1 (en) | 2000-07-06 | 2001-06-29 | Use of substituted indole compounds for treating sphincter incontinence |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21618600P | 2000-07-06 | 2000-07-06 | |
US21618500P | 2000-07-06 | 2000-07-06 | |
US60/216,185 | 2000-07-06 | ||
US60/216,186 | 2000-07-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002003989A2 WO2002003989A2 (en) | 2002-01-17 |
WO2002003989A3 true WO2002003989A3 (en) | 2002-07-18 |
Family
ID=26910745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/021081 WO2002003989A2 (en) | 2000-07-06 | 2001-06-29 | Use of substituted indole compounds for treating sphincter incontinence |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001271781A1 (en) |
WO (1) | WO2002003989A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129264B2 (en) | 2003-04-16 | 2006-10-31 | Bristol-Myers Squibb Company | Biarylmethyl indolines and indoles as antithromboembolic agents |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
US20080227814A1 (en) * | 2004-01-29 | 2008-09-18 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
BRPI0712103A2 (en) | 2006-05-22 | 2012-01-17 | Hormos Medical Corp | method of treating chronic non-bacterial prostatitis and to prevent the progression of benign prostatic hyperplasia (bph) or prostate cancer in men |
HUE055321T2 (en) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
MX2018007079A (en) | 2015-12-09 | 2018-11-12 | The Board Of Trustees Of Univ Of Illinois | Benzothiophene-based selective estrogen receptor downregulators. |
CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109641874A (en) | 2016-05-10 | 2019-04-16 | C4医药公司 | C for target protein degradation3The glutarimide degron body of carbon connection |
EA201990187A1 (en) | 2016-07-01 | 2019-07-31 | Г1 Терапьютикс, Инк. | PYRIMIDINE ANTIPROLIFERATION AGENTS |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
AU2018205262A1 (en) | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
CA3052810A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
AU2018291026B2 (en) | 2017-06-29 | 2022-09-01 | G1 Therapeutics, Inc. | Morphic forms of GIT38 and methods of manufacture thereof |
CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026876A1 (en) * | 1996-01-29 | 1997-07-31 | Eli Lilly And Company | Methods of increasing sphincter competence |
EP0802184A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | N-Benzyl-2-phenylindoles as estrogenic agents |
EP0802183A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | Estrogenic agents |
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
WO1999059969A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
WO1999059581A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
WO2002003976A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
-
2001
- 2001-06-29 AU AU2001271781A patent/AU2001271781A1/en not_active Abandoned
- 2001-06-29 WO PCT/US2001/021081 patent/WO2002003989A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997026876A1 (en) * | 1996-01-29 | 1997-07-31 | Eli Lilly And Company | Methods of increasing sphincter competence |
EP0802184A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | N-Benzyl-2-phenylindoles as estrogenic agents |
EP0802183A1 (en) * | 1996-04-19 | 1997-10-22 | American Home Products Corporation | Estrogenic agents |
US5880137A (en) * | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
WO1999059969A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
WO1999059581A1 (en) * | 1998-05-15 | 1999-11-25 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens |
WO2002003976A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
Non-Patent Citations (1)
Title |
---|
CARDOZO L ET AL: "SEX HORMONES AND THE FEMALE LOWER URINARY TRACT", PHYSIOTHERAPY, CHARTERED SOCIETY OF PHYSIOTHERAPY, LONDON, GB, vol. 80, no. 3, 1 March 1994 (1994-03-01), pages 135 - 138, XP000670049, ISSN: 0031-9406 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002003989A2 (en) | 2002-01-17 |
AU2001271781A1 (en) | 2002-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002003989A3 (en) | Use of substituted indole compounds for treating sphincter incontinence | |
WO2002003992A3 (en) | Use of substituted indole compounds for treating prosthesis-related bone degeneration | |
WO2002003987A3 (en) | Pharmaceutical compositions of estrogenic agents | |
WO2002003988A3 (en) | Use of substituted indole compounds for treating neuropeptide y-related conditions | |
WO2002003986A3 (en) | Use of substituted indole compounds for treating breast disorders | |
WO2002003976A3 (en) | Combinations of bisphosphonates, estrogenic agents and optionally estrogens | |
WO2002003977A3 (en) | Combinations of statins, estrogenic agents and optionally estrogens | |
AP2001002241A0 (en) | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents. | |
WO2002003990A3 (en) | Use of substituted insole compounds for treating excessive intraocular pressure | |
AU4925199A (en) | Quinolin-2-one derivatives useful as anticancer agents | |
ZA200600475B (en) | Pyrimidine-2,4-dione derivatives as gonadotripin-releasing hormone receptor antagonists | |
WO2002003991A3 (en) | Use of substituted indole compounds for increasing nitric oxide synthase activity | |
AU4257901A (en) | Triarylimidazole derivatives as cytokine inhibitors | |
AU7315301A (en) | Compounds and compositions for delivering active agents | |
ES2129279A1 (en) | Organic compounds | |
CA2327253A1 (en) | Sulfonamide-containing indole compounds | |
ES2171428T3 (en) | DERIVATIVES OF GALANTAMINE, A PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS. | |
CA2313122A1 (en) | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents | |
CA2094335A1 (en) | 4,1-benzoxazepin derivatives and their use | |
GB0031302D0 (en) | Napthalene derivatives | |
CA2290766A1 (en) | Method of treating nitrate-induced tolerance | |
CA2280850A1 (en) | Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies | |
ATE398627T1 (en) | C-2-MODIFIED ERYTHROMYCIN DERIVATIVES | |
AP2001002302A0 (en) | 13-Methyl erythromycin derivatives. | |
NZ527522A (en) | Use of a chemopreventative agent in a method for chemoprevention of prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |